Study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

New research reveals GPR31’s role in immune response to gut infections

Researchers from Osaka University discover that the GPR31 path in ‘gut surveillance’ cells detects bacterial metabolites and triggers immune responses, opening new possibilities for drug

October 22, 2024

Trinity Invests $25M Moxe Health for Health Data Interoperability

What You Should Know: – Trinity Capital Inc. (NASDAQ: TRIN), a leading provider of growth capital to innovative companies announced a $25M investment in Moxe

March 2, 2024

Clinical trial reveals dapagliflozin’s impact on heart failure and type 2 diabetes management

Researchers conducted a clinical trial on the effects of dapagliflozin on the urinary albumin-to-creatinine ratio (UACR) in patients with heart failure (HF) and type 2

November 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.